|
|
|
| Mechanism prediction of Guishao Pingchan Formula against Parkinson′s disease based on IPA platform |
| WU Qian TAN Lijuan ZHANG Jionglu HE Taozhi CHEN Lingxiu YAN Xianxin LIU Hongjie |
| College of Traditional Chinese Medicine, Ji′nan University, Guangdong Province, Guangzhou 510632, China |
|
|
|
Abstract Objective To explore the molecular mechanism of Guishao Pingchan Formula against Parkinson′s disease (PD) based on ingenuity pathway analysis (IPA) platform. Methods The chemical constituents of Guishao Pingchan Formula [Carapax et Plastrum Testudinis (Guijia), Radix Paeoniae Alba (Baishao), Rhizoma Ligustici Chuanxiong (Chuanxiong) and Rhizoma Gastrodiae (Tianma)] were searched from China national knowledge infrastructure (CNKI), viper database (VIP), China biology medicine disc (CBMdisc), Chinese materia medica, PubMed, Web of Science, SciFinder Scholar and active target proteins were retrieved from PubChem from April 1994 to December 2019. Meanwhile, PD related genes were retrieved from Gene. Finally, target proteins of Guishao Pingchan Formula and PD related genes were uploaded to IPA platform, and the molecular networks and classical biological pathways involved in them were compared. Results Three hurdred and twenty-three human active target proteins (58 Guijia, 119 Baishao, 72 Chuanxiong, 74 Tianma) and 392 PD related genes were obtained, then a major molecular network in which both were involved were built. Meanwhile, 10 main canonical pathways involved together were selected, such as G-protein coupled receptors signaling. Conclusion Guishao Pingchan Formula might play an anti-PD role by regulating G-protein coupled receptors signaling and other pathways.
|
|
|
|
|
|
[1] Chen S，Chan P，Sun S，et al. The recommendations of Chinese Parkinson′s disease and movement disorder society consensus on therapeutic management of Parkinson′s disease [J]. Transl Neurodegener，2016，5（1）：12.
[2] 霍绮雯，谭峰，林东雄，等.定振丸对帕金森病大鼠神经递质及黑质多巴胺能神经元氧化应激的改善作用[J].中成药，2020，42（3）：604-610.
[3] 杨应浩，姚谦明，程国雄，等.丘脑底核脑深部电刺激术辅助治疗帕金森病的临床效果[J].中国医药导报，2019， 16（5）：68-71.
[4] 王林.左旋多巴联合普拉克索治疗帕金森病的有效性及安全性[J].中国医药指南，2017，15（33）：65-66.
[5] 王贤正，钱梦，谢鸣.中医药联合多巴制剂治疗帕金森病的临床研究进展[J].中国药师，2017，20（9）：1578-1583.
[6] 黄少东，梁健芬，陈月桥.中药复方联合复方左旋多巴治疗帕金森病的临床研究进展[J].湖南中医药大学学报，2018，38（12）：1471-1475.
[7] 李彪，汪瀚，杨文明.中医药治疗帕金森病临床研究进展[J].辽宁中医药大学学报，2017，19（7）：130-133.
[8] Zhao J，Jiang P，Zhang W. Molecular networks for the study of TCM harmacology [J]. Brief Bioinform，2010，11（4）：417-430.
[9] Hopkins AL. Network pharmacology：the next paradigm in drug discovery [J]. Nat Chem Biol，2008，4（11）：682-690.
[10] Drews J. Drug discovery：a historical perspective [J]. Science，2000，287（5460）：1960-1964.
[11] 谢腾，王升，马炯，等.生物信息学在中药资源研究中的应用[J].中国中药杂志，2012，37（24）：3684-3689.
[12] 刘春杰，董立珉，刘郁.中西医结合治疗帕金森病[J].时珍国医国药，2006，17（3）：428-429.
[13] 彭根兴，李绍敏.帕金森病中医辨证诊治探讨[J].中医药临床杂志，2019，31（2）：378-381.
[14] 冯其美，王亚丽，李智山，等.疏、补、消三法论治帕金森病[J].中医学报，2019，34（12）：2500-2503.
[15] 杨媛，苗素华，周荣凇，等.帕金森病中医治疗现状分析及政策建议[J].中国医药导报，2019，16（35）：44-47.
[16] 王春燕，曾和平，王婷婷，等.中药龟板活性部位GC-MS生物活性指纹图谱和应用[J].中南药学，2007，5（1）：74-78.
[17] 周笑莉，刘忆思，陈东风，等.龟板提取物调控Otx2基因促进神经干细胞向多巴胺神经元分化的研究[J].中药新药与临床药理，2017，2（28）：171-176.
[18] 张淑香，王术平，田伟，等.中药白芍在帕金森领域的研究进展[J].中医药学报，2015，43（3）：133-136.
[19] 张大燕，文欢，王伟，等.天麻对帕金森小鼠神经元保护作用机制的转录组学分析[J].中国实验方剂学杂志，2018，24（16）：73-81.
[20] 张立娟，张倩，王康锋，等.天麻钩藤饮对帕金森病模型大鼠行为学及纹状体内多巴胺含量的影响[J].江苏中医药，2018，50（2）：79-82.
[21] 王丹巧，王巍，景富春，等.川芎嗪对左旋多巴处理的PD大鼠纹状体细胞外液DA及其代谢产物、羟自由基水平的影响[J].中国药学杂志，2007，42（1）：28-31.
[22] 杨秀娟，洪燕龙，阮克锋，等.中药治疗帕金森病临床及升高脑内多巴胺含量的研究进展[J].中药药理与临床，2012，28（2）：187-191.
[23] 杨璇，赵海军，崔贺斌，等.多巴胺受体与帕金森病[J].脑与神经疾病杂志，2019，27（3）：192-196.
[24] Nakano N，Matsuda S，Ichimura M，et al. PI3K/AKT signaling mediated by G protein coupled receptors is involved in neurodegenerative Parkinson′s disease （review） [J]. Int J Mol Med，2017，39（2）：253-260.
[25] Oeckl P，Hengerer B，Ferger B. G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson′s disease [J]. Exp Neurol，2014，257（6）：1-9. |
|
|
|
